作为一种潜在的生物标志物和治疗点在新诊断的2型糖尿病中
Ismail Demir1, Ismail Yilmaz2, Ersan Horoz2
1Department of Internal Medicine, Health Sciences University, Izmir, Bozyaka Training and Research Hospital, 35170, Karabaglar, Izmir, Turkey. dr.ismail.demir.36@gmail.com.
Irish journal of medical science
|July 7, 2023
概括
在新诊断的2型糖尿病 (T2DM) 和代谢综合征患者中,母酶水平升高. 增加的母酶与关键的代谢和炎症标志物相关,这表明它在T2DM病变发生过程中的作用.
科学领域:
- 生物化学 生物化学
- 内分泌学 在内分泌学.
- 代谢研究研究 代谢研究
背景情况:
- 2 型糖尿病 (T2DM) 涉及复杂的代谢失调,其中含有增加的阿迪波金和炎症化学因子.
- 胰岛素-葡萄糖代谢受损是T2DM的一个标志.
- 具有已知的糖化位点的蛋白质溶解酶母酶与葡萄糖代谢有关.
研究的目的:
- 评估最近被诊断为T2DM患者的母质酶和代谢参数之间的关系.
- 探索母酶在糖尿病发展中的潜在作用.
主要方法:
- 测量代谢实验室参数,包括生物化学测试和血液图.
- 高灵敏性C反应蛋白 (hsCRP) 和母质酶水平的量化.
- 评估胰岛素抵抗的恒温模式评估 (HOMA-IR).
主要成果:
- 与对照组相比,T2DM患者的循环矩形酶水平显著更高.
- 在患有代谢综合征的个体中观察到升的母酶水平.
- 在T2DM,高HOMA-IR,hsCRP和母酶水平之间发现了积极的相关性.
结论:
- 这项研究是首次报告T2DM和/或代谢综合征新诊断的母质酶升高.
- 松酶水平与代谢和炎症标志物有积极的相关性,这表明它在T2DM病变发生过程中发挥了作用.
- 孕酶可能是T2DM和葡萄糖代谢障碍的新疗法标.
相关概念视频
Glucagon-like Receptor Agonists
365
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
365
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214


